Blood pressure surveillance in cancer patients treated with immune checkpoint inhibitors.
Journal
Journal of human hypertension
ISSN: 1476-5527
Titre abrégé: J Hum Hypertens
Pays: England
ID NLM: 8811625
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
26
01
2023
accepted:
06
04
2023
revised:
20
03
2023
medline:
9
11
2023
pubmed:
20
4
2023
entrez:
19
04
2023
Statut:
ppublish
Résumé
Immune checkpoint inhibitors (ICI) are cancer therapies that have been associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Blood pressure (BP) measurements are routinely performed during day oncology center visits for administration of ICI therapy but are often not assessed temporally to screen and monitor hypertension, which could independently increase the risk of ASCVD in cancer survivorship. This study reports the feasibility of using serial BP measurements from routine visits to day oncology center to diagnose and monitor hypertension control in cancer patients receiving ICIs.
Identifiants
pubmed: 37076569
doi: 10.1038/s41371-023-00831-z
pii: 10.1038/s41371-023-00831-z
pmc: PMC10632129
doi:
Substances chimiques
Immune Checkpoint Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1043-1046Informations de copyright
© 2023. The Author(s).
Références
J Clin Oncol. 2013 Oct 10;31(29):3673-80
pubmed: 24002505
Circulation. 2016 Mar 15;133(11):1104-14
pubmed: 26976915
Hypertension. 2022 Nov;79(11):2611-2621
pubmed: 36093785
Circulation. 2015 Jan 27;131(4):e29-322
pubmed: 25520374
JACC CardioOncol. 2022 Jun 21;4(2):149-165
pubmed: 35818559
J Am Coll Cardiol. 2022 Feb 15;79(6):577-593
pubmed: 35144750
Eur Heart J. 2021 Dec 21;42(48):4964-4977
pubmed: 34529770
Eur Heart J. 2018 Sep 1;39(33):3021-3104
pubmed: 30165516
JACC CardioOncol. 2022 Dec 20;4(5):579-597
pubmed: 36636451
Circulation. 2020 Dec 15;142(24):2299-2311
pubmed: 33003973
Eur Heart J. 2022 Nov 1;43(41):4229-4361
pubmed: 36017568